Repare Therapeutics’ (RPTX) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Repare Therapeutics (NASDAQ:RPTX) in a research note released on Thursday morning, Benzinga reports. They currently have a $10.00 price objective on the stock.

Separately, Lifesci Capital raised Repare Therapeutics to a “strong-buy” rating in a research report on Monday, July 29th.

Repare Therapeutics Trading Down 0.6 %

NASDAQ RPTX traded down $0.02 during trading hours on Thursday, reaching $3.35. 3,511 shares of the company traded hands, compared to its average volume of 165,948. The stock has a market capitalization of $142.19 million, a PE ratio of -3.07 and a beta of 0.72. Repare Therapeutics has a 12 month low of $2.71 and a 12 month high of $8.49. The company has a 50 day moving average of $3.23 and a two-hundred day moving average of $3.39.

Repare Therapeutics (NASDAQ:RPTX) last issued its quarterly earnings results on Tuesday, August 6th. The company reported ($0.82) EPS for the quarter, topping the consensus estimate of ($0.85) by $0.03. The business had revenue of $1.07 million for the quarter, compared to analysts’ expectations of $4.02 million. Repare Therapeutics had a negative net margin of 99.76% and a negative return on equity of 31.11%. On average, equities research analysts anticipate that Repare Therapeutics will post -2.15 earnings per share for the current year.

Institutional Investors Weigh In On Repare Therapeutics

Institutional investors have recently modified their holdings of the business. Vontobel Holding Ltd. boosted its stake in Repare Therapeutics by 20.0% in the third quarter. Vontobel Holding Ltd. now owns 24,000 shares of the company’s stock valued at $83,000 after acquiring an additional 4,000 shares during the period. Exchange Traded Concepts LLC boosted its position in Repare Therapeutics by 21.2% during the 3rd quarter. Exchange Traded Concepts LLC now owns 50,441 shares of the company’s stock valued at $174,000 after purchasing an additional 8,809 shares during the period. Blue Owl Capital Holdings LP grew its stake in Repare Therapeutics by 8.0% during the 2nd quarter. Blue Owl Capital Holdings LP now owns 3,372,499 shares of the company’s stock worth $11,129,000 after buying an additional 250,000 shares during the last quarter. Squarepoint Ops LLC increased its position in Repare Therapeutics by 428.4% in the second quarter. Squarepoint Ops LLC now owns 142,974 shares of the company’s stock worth $472,000 after buying an additional 115,916 shares during the period. Finally, Marshall Wace LLP bought a new stake in Repare Therapeutics in the second quarter valued at $273,000. Institutional investors own 85.09% of the company’s stock.

About Repare Therapeutics

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.